Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids
A Hybrid drug which comprises the incorporation of two drug pharmacophores in one single
molecule are basically designed to interact with multiple targets or to amplify its effect …
molecule are basically designed to interact with multiple targets or to amplify its effect …
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights
P Bose, Y Dai, S Grant - Pharmacology & therapeutics, 2014 - Elsevier
Initially regarded as “epigenetic modifiers” acting predominantly through chromatin
remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase …
remodeling via histone acetylation, HDACIs, alternatively referred to as lysine deacetylase …
[HTML][HTML] Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications
Genetic abnormalities have been conventionally considered as hallmarks of cancer.
However, studies over the past decades have demonstrated that epigenetic regulation also …
However, studies over the past decades have demonstrated that epigenetic regulation also …
Synthesis and anticancer activities of thieno [3, 2-d] pyrimidines as novel HDAC inhibitors
Q Tan, Z Zhang, J Hui, Y Zhao, L Zhu - Bioorganic & medicinal chemistry, 2014 - Elsevier
Abstract A series of thieno [3, 2-d] pyrimidines bearing a hydroxamic acid moiety as novel
HDAC inhibitors were designed and synthesized. The structures of the new synthesized …
HDAC inhibitors were designed and synthesized. The structures of the new synthesized …
Design, synthesis and biological evaluation of 4′-demethyl-4-deoxypodophyllotoxin derivatives as novel tubulin and histone deacetylase dual inhibitors
A new class of 4′-demethyl-4-deoxypodophyllotoxin derivatives has been designed and
synthesized as tubulin–HDAC dual inhibitors. Biological evaluation of these hybrids …
synthesized as tubulin–HDAC dual inhibitors. Biological evaluation of these hybrids …
Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition
M Batalo, P Bose, B Holkova, S Grant - Resistance to proteasome …, 2014 - Springer
Although approved for over a decade, the clinical utility of proteasome inhibitors (PIs)
remains largely restricted to the treatment of patients with multiple myeloma (MM) and …
remains largely restricted to the treatment of patients with multiple myeloma (MM) and …
A Comparison of m-Carboxycinnamic Acid Bishydroxamide with Trichostatin A as Histone Deacetylase Inhibitor on the Developmental Competence of Somatic Cell …
이미란， 박상훈， 김태석， 백상기， 진상진， 고영규… - 농업생명과학 …, 2014 - dbpia.co.kr
The cloning efficiency is extremely low despite successful somatic cell nuclear transfer
(SCNT) method producing cloned animals in several mammals. In general, faulty …
(SCNT) method producing cloned animals in several mammals. In general, faulty …